According to the health ministry of Uzbekistan, 18 kids have passed away after ingesting cough medicine made by Indian pharmaceutical company Marion Biotech.
According to the ministry, early examinations revealed that a batch of the medication contained the hazardous chemical ethylene glycol.
It claimed that the Dok-1 Max syrup was administered to the kids without a prescription.
They ingested more than the recommended dose for youngsters as well.
The Gambia made a similar claim a few weeks prior, linking infant fatalities to cough syrups supplied by another Indian company. Now Uzbekistan has made the same claim.
The national drug regulator of Uzbekistan ...and India's health ministry has been in "frequent touch over the situation" since December 27, according to a statement from the Indian health ministry. It further stated that the Marion Biotech plant in Noida, Uttar Pradesh, had undergone a health check.
The statement said, "The samples of the cough syrup have been removed from the production premises and forwarded to Chandigarh's Regional Drugs Examination Laboratory for testing.
news source A Marion Biotech official was reported by ANI as claiming that the business had temporarily stopped making the syrup. He further stated that the firm would act appropriately in light of the government's investigation. Near Delhi, the capital of India sits Noida, where Marion Biotech is headquartered. Although the business's website is presently offline, it was established in 1999, and according to its LinkedIn page, its goods are "familiar brands in Central Asian countries, Central and Latin America, South East Asia, and Africa."
A third of all pharmaceuticals in the world are made in India, primarily as generic medications.
The nation, dubbed as the "world's pharmacy," provides the majority of the medical requirements of developing nations and is home to some of the pharmaceutical businesses with the greatest rate of growth.
According to a statement from the Uzbek government dated December 27, Dok-1 Max syrup and pills have been supplied there since 2012."It was discovered that the deceased youngsters took this medicine at home for two to seven days, three to four times per day, 2.5 to five milliliters, which exceeds the normal dose of the drug for children," the ministry stated.
The timeline of the fatalities was not made clear in the announcement. According to a 23 December report from BBC Monitoring, which was cited by the news website Gazeta.uz, Uzbek authorities were looking into "reports that 15 youngsters died in the central Samarkand area over the previous two months after consuming an Indian cough syrup."
According to a news article published on December 26 by the Podrobno. uz website, between September and December, Dok-1 Max, a cough syrup developed in India, "supposedly" caused acute renal failure in 21 infants, 15 of whom were under the age of three.Three of the patients recovered. Preliminary laboratory examinations have revealed that this series of Dok-1 Max syrup includes ethylene glycol, the government added.
When 66 children in The Gambia died from kidney damage in October, the World Health Organization (WHO) issued a global notice and blamed four cough syrups produced in India. Tests on samples of the syrup, according to the report, revealed that they contained unsafe levels of the hazardous chemicals diethylene glycol and ethylene glycol.
The charges have been refuted by the Indian government as well as Maiden Pharmaceuticals. India stated earlier in December that testing on the four syrups revealed that they met requirements, and a government source told that the WHO had been "presumptuous" in attributing the problem to the syrups. But the WHO insisted that it supported the adopted action.
Following weeks of inquiry, a parliamentary committee in The Gambia last week recommended charging Maiden Pharmaceuticals. The committee suggested that the government outlaw the company's whole line of goods.
According to the ministry, early examinations revealed that a batch of the medication contained the hazardous chemical ethylene glycol.
It claimed that the Dok-1 Max syrup was administered to the kids without a prescription.
They ingested more than the recommended dose for youngsters as well.
The Gambia made a similar claim a few weeks prior, linking infant fatalities to cough syrups supplied by another Indian company. Now Uzbekistan has made the same claim.
The national drug regulator of Uzbekistan ...and India's health ministry has been in "frequent touch over the situation" since December 27, according to a statement from the Indian health ministry. It further stated that the Marion Biotech plant in Noida, Uttar Pradesh, had undergone a health check.
The statement said, "The samples of the cough syrup have been removed from the production premises and forwarded to Chandigarh's Regional Drugs Examination Laboratory for testing.
news source A Marion Biotech official was reported by ANI as claiming that the business had temporarily stopped making the syrup. He further stated that the firm would act appropriately in light of the government's investigation. Near Delhi, the capital of India sits Noida, where Marion Biotech is headquartered. Although the business's website is presently offline, it was established in 1999, and according to its LinkedIn page, its goods are "familiar brands in Central Asian countries, Central and Latin America, South East Asia, and Africa."
A third of all pharmaceuticals in the world are made in India, primarily as generic medications.
The nation, dubbed as the "world's pharmacy," provides the majority of the medical requirements of developing nations and is home to some of the pharmaceutical businesses with the greatest rate of growth.
According to a statement from the Uzbek government dated December 27, Dok-1 Max syrup and pills have been supplied there since 2012."It was discovered that the deceased youngsters took this medicine at home for two to seven days, three to four times per day, 2.5 to five milliliters, which exceeds the normal dose of the drug for children," the ministry stated.
The timeline of the fatalities was not made clear in the announcement. According to a 23 December report from BBC Monitoring, which was cited by the news website Gazeta.uz, Uzbek authorities were looking into "reports that 15 youngsters died in the central Samarkand area over the previous two months after consuming an Indian cough syrup."
According to a news article published on December 26 by the Podrobno. uz website, between September and December, Dok-1 Max, a cough syrup developed in India, "supposedly" caused acute renal failure in 21 infants, 15 of whom were under the age of three.Three of the patients recovered. Preliminary laboratory examinations have revealed that this series of Dok-1 Max syrup includes ethylene glycol, the government added.
When 66 children in The Gambia died from kidney damage in October, the World Health Organization (WHO) issued a global notice and blamed four cough syrups produced in India. Tests on samples of the syrup, according to the report, revealed that they contained unsafe levels of the hazardous chemicals diethylene glycol and ethylene glycol.
The charges have been refuted by the Indian government as well as Maiden Pharmaceuticals. India stated earlier in December that testing on the four syrups revealed that they met requirements, and a government source told that the WHO had been "presumptuous" in attributing the problem to the syrups. But the WHO insisted that it supported the adopted action.
Following weeks of inquiry, a parliamentary committee in The Gambia last week recommended charging Maiden Pharmaceuticals. The committee suggested that the government outlaw the company's whole line of goods.
Tags:
Health News